Sage Therapeutics depression drug disappoints
![Photo: CARLO ALLEGRI/REUTERS / X90181](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13059313.ece/ALTERNATES/schema-16_9/doc7g8jgq5k9tk9idim7cv.jpg)
Sage Therapeutics took an 18.8 percent dive to USD 59.15 in the US pre-market after the US biotech firm generated disappointing results from a trial involving a potential treatment for severe depression.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Fate of Biogen’s stock rides on Alzheimer’s drug decision
For subscribers